PMLS 2018 SOUTH – TEXAS 2018-09-21T14:27:35+00:00
Loading...

The Precision Medicine Leaders Summit is proud to present our first event located in the South of the country. Known by some as the Third Coast for life sciences, the Texas Medical Center will host our inaugural PMLS South event this November 29-30.

Continuing the successes of our events in San Diego and Jersey City, we hope you will join us for the most thought-provoking Precision Medicine event in the marketplace. Our speakers include clinicians, industry experts, academics, regulators, payers, genetic counselors, bioinformaticians, and many more who are shaping the way Precision Medicine is implemented into the healthcare systems globally.

Join us for panel discussions, keynotes, roundtables, networking, exhibits, and opening reception to hear from thought leaders who are making the promise of Precision Medicine a reality.

REGISTER TODAY

SPEAKERS

Hannah Mamuszka

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Hannah Mamuszka

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Hannah Mamuszka

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Hannah Mamuszka

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Hannah Mamuszka

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Werner Verbiest

Global Head, Janssen Diagnostics

Werner joined Johnson & Johnson in 1991 with the International Clinical R&D group of the Janssen Research Foundation, where he was active in HIV drug development and Hepatitis B vaccine development. In 1997, Werner joined Virco, as Project Director, Business Development. He was promoted to Managing Director, Virco Ireland in 2002 and became Vice President, New Products and Pharma Business.
He is currently Global Head Janssen Diagnostics, comprising the legacy organizations of Virco, Veridex and Johnson and Johnson’s Companion Diagnostics Center of Excellence. Over these years, he has been active in all phases of HIV clinical trial strategy and implementation, biomarker development (Collaborative Surrogate Marker Validation working groups with FDA and EMA), and has contributed to numerous papers and presentations on pharmacogenomics and personalized medicine.

In his current role as Global Head, Werner plays a leading role in advocating for and actualizing a personalized medicine approach within JnJ, but also outside JnJ, including several board seats in different “precision medicine” and Dx organizations.

Virginia M. Miller, MBA, PhD

Professor, Surgery and Physiology, Director, Women’s Health Research Center, Mayo Clinic

Dr. Miller is Professor of Surgery and Physiology and Director of the Women’s Health Research Center at Mayo Clinic, Rochester, MN. She received a BS in education from Slippery Rock University, Slippery Rock, PA, a MBA from the University of Minnesota, and her PhD in Physiology from the University of Missouri, Columbia, MO. Her research includes work with experimental animals and clinical studies focusing on how sex steroids, like estrogen, and conditions unique to women such as pregnancy and menopause affect cardiovascular health and cognition. She currently serves as Principal Investigator of the Mayo Clinic Building Interdisciplinary Careers in Women’s Health (BIRCWH) scholars program and was the previous Principal Investigator for the Mayo Clinic Specialized Center of Research on Sex Differences. She has authored over 250 original publications and reviews. She has received numerous awards including the Bernadine Healy Award for Visionary Leadership in Women’s Health, the Women’s Day Magazine Red Dress Award for her work in research and advocacy for women’s health, and the Paul M. Vanhoutte Named Lecture in Vascular Pharmacology from the American Society for Pharmacology and Experimental Therapeutics. She has worked with international groups in the promotion for the inclusion of sex and gender variables in basic and medical curricula and research. In addition to service on various grant review panels and editorial boards for scientific journals, she served as a member of the governing council for the American Physiological Society (APS) and as President of the Organization for the Study of Sex Differences (OSSD).

AGENDA

WEDNESDAY JUNE 27th, 2018

THURSDAY JUNE 28th, 2018

THURSDAY NOVEMBER 29th, 2018

7:45-8:45am

Registration & Breakfast Buffet

9:00-9:30am

Keynote Address:

Jennifer Wargo, M.D., M.M.Sc.

Associate Professor, Dept. of Surgical Oncology - Div. of Surgery & Dept. of Genomic Medicine - Div. of Cancer Medicine,The University of Texas MD Anderson Cancer Center, Houston, TX

 

9:30–10:25am

Immunotherapies and Their Impact on Precision Medicine

Moderator: Jennifer Wargo, M.D., M.M.Sc. Associate Professor, Dept. of Surgical Oncology - Div. of Surgery & Dept. of Genomic Medicine - Div. of Cancer Medicine,The University of Texas MD Anderson Cancer Center, Houston, TX

Panelists: Leslie Williams, MBA, CEO - ImmusanT

10:25–10:55am

Coffee & Networking

 11:00- 11:50am

11:55–12:15pm

Precision 20

12:20–1:10pm

LUNCH

1:10– 2:00pm

Innovation in Genomic Medicine Implementation

Moderator: Erica Ramos, MS, LCGC, President, National Society of Genetic Counselors and Dir & Head of Clinical Business Development at Geisinger National Precision Health

Panelists: Lisa Alderson, CEO Genome Medical

Genomic medicine is exciting and the stories about the impact to patients are compelling. Consider your patient panel – for every 100 patients, 2-3 carries a pathogenic genetic variant in a gene for a disease like Lynch syndrome, familial hypercholesterolemia and other hereditary cancer and cardiac diseases. These diseases are actionable and potentially preventable. Do you know who these patients are in your clinic?

This session will focus on practical but innovative ways for clinicians to integrate genomics into their practices and give you a glimpse into the future of the delivery of genetic services.

2:00 - 2:20pm

Precision 20

2:20–3:10pm

Molecular Tumor Boards Impact on Precision Medicine

3:10-3:40pm

Coffee & Networking

3:40- 4:30pm

Digital Pathology

Moderator: Michael Riben, MD, Director of Anatomic Pathology Informatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Panelists:

4:35 - 5:30pm

Efforts to Implement Precision Medicine in Cardiovascular Disease

Moderator: Hannah Mamuska, CEO Alva 10

Panelists: 

5:30-6:40pm

Roundtables

6:45-8:45pm

Networking Reception at JLABS - TMC - enjoy drinks and hors d'houvres with fellow attendees,speakers and sponsors.

FRIDAY NOVEMBER 30th, 2018

7:45-8:25am

Breakfast Buffet

8:25-8:30am

Day One Recap

8:30–9:00am

Keynote:

9:05–10:05am

Precision Medicine Clinical Trials and Novel Designs: Levering Data, ‘Omics’, AI and Policy

Moderator: Arturo Loiaza Bonilla, MD, Vice Chariman of Medical Oncology, Cancer Treatment Centers of America

Panelists: Selin Kurnaz, CEO - Massive Bio

The paradigm change from the ‘phenotype-to-genotype’ to the ‘genotype-to-phenotype’ approach has revolutionized R&D and Clinical trials in oncology and other diseases. This panel will discuss the impact of novel approaches to clinical trial design, including the use of technology, biomarker data and the current regulatory landscape which is moving the needle forward in earlier access and approval of promising compounds. The audience will be able to learn further about ‘basket’, ‘umbrella’, ‘seamless’, ‘adaptive’ design trials, synthetic control arms, ‘Just-In-Time (JIT) trials, as will have the opportunity to how different stakeholders are adapting to recent FDA policies and regulations for their R&D and clinical trial matching enrollment.

10:05 - 10:35am

Coffee & Networking

10:40-11:40am

AI in Precision Medicine

Moderator: Severance McLaughlin

11:40–12:00noon

Precision 20

12:00-12:50pm

LUNCH

12:50–1:50pm

Women’s Health & Precision Medicine

Moderator: Amy Miller CEO – Society for Women’s Health Research

Panelists: Katie Johansen Taber, Myriad Women’s Health, Debu Tripathy, MD Anderson, Virginia Miller, Mayo Clinic

1:55–2:15pm

Transforming Healthcare Through AI-driven Clinical Genomic Insights to Improve Patient Lives

Charlene Son Rigby, CBO Fabric Genomics

Precision medicine promises customized patient therapy by maximizing treatment effectiveness and minimizing side effects. Genomics is a critical tool in making precision medicine a reality. With genomic testing becoming more mainstream within the U.S. and worldwide, clinical and hospital laboratories are starting to publish compelling data on its utility. Yet adoption continues to be hampered by cost. Technology advances are critical to lower costs and accelerate adoption. The importance of technology, automation and the role for AI in genomic data interpretation will be discussed along with patient examples including ending her family’s diagnostic odyssey through whole exome testing.

2:15–2:45pm

COFFEE & NETWORKING

2:50–3:30pm

How is Precision Medicine Being Implemented in Clinical Care Settings both Large & Small?

Moderator: Erik Halvorsen, PhD, Director, Texas Medical Center Innovation Institute

3:35–3:55pm

Precision 20

4:00–4:50pm

Innovation is the Key Driver in Progress to a More Complete Picture in Precision Medicine – How Do we Move the Needle More Efficiently?

Moderator: Tom Luby, Ph.D, Head of JLABS @ TMC 

4:50-4:55pm

CLOSING REMARKS

SPONSORS

Novartis
SomaLogic
Medidata
Novartis

VENUE

TMC Innovation Institute

2450 Holcombe Blvd., Suite X
Houston, TX 77021
Phone: 713-791-8846
www.tmcinnovation.org

Texas Medical Center Innovation Institute

HOTEL ZAZA HOUSTON | MUSEUM DISTRICT

5701 Main Street

Houston, Texas 77005

Phone: 713.526.1991

Toll-Free Reservations: 888.880.3244

Email: houstonmuseumdistrict@hotelzaza.com

Website: www.hotelzaza.com

HOUSTON MARRIOTT MEDICAL CENTER/MUSEUM DISTRICT

6580 Fannin Street

Houston, Texas 77030

Phone: 713.796.0080

Website: www.marriott.com

There is NO parking available at the event venue.

There is no parking available at the event venue. We will be running a shuttle service form the two main hotels, Hotel Zaza, and the Houston Marriott Medical Center/Museum District.

REGISTER TODAY
REGISTER

SIGN UP FOR UPDATES

Receive information about our 2018 conference speakers, schedule and registration.
REGISTER